| P50 | author | Munir Pirmohamed | Q20127995 |
| P2093 | author name string | B K Park | |
| | S Madden | |
| P2860 | cites work | Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4 | Q72968489 |
| | Irreversible binding of zomepirac to plasma protein in vitro and in vivo | Q24564067 |
| | Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity | Q28235766 |
| | Acute and chronic drug-induced hepatitis | Q28288881 |
| | Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 |
| | A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein | Q28319102 |
| | Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure | Q28327668 |
| | Flutamide-induced liver failure | Q28335561 |
| | A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis | Q28366441 |
| | The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes | Q33196792 |
| | Drugs 5 years later: carbamazepine | Q33462737 |
| | Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug | Q34183015 |
| | Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure | Q34303815 |
| | Metabolism and bioactivation of clozapine by human liver in vitro | Q34320958 |
| | Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions | Q34323071 |
| | Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms | Q34345969 |
| | The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes | Q34346464 |
| | Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. | Q34358782 |
| | A screening test for slow metabolisers of tolbutamide | Q34358861 |
| | Genetic predisposition to alcoholic liver disease | Q34396214 |
| | Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes | Q34397894 |
| | The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients | Q34403177 |
| | Idiosyncratic drug reactions: a mechanistic evaluation of risk factors | Q34403403 |
| | The glutathione S-transferases: an update | Q34497816 |
| | Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization | Q34559954 |
| | Systemic glutathione deficiency in symptom-free HIV-seropositive individuals | Q34668415 |
| | Genetic Polymorphisms in the 5′-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P450IIE1 Gene1 | Q34677484 |
| | Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac | Q41086481 |
| | The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity | Q41097351 |
| | P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. | Q41142872 |
| | Metabolism of carbamazepine | Q41533185 |
| | Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. | Q41574301 |
| | The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. | Q41935493 |
| | N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity | Q42000770 |
| | Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis | Q42210491 |
| | Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. | Q42213026 |
| | CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes | Q42275613 |
| | Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection | Q42279836 |
| | Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy | Q42281277 |
| | The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. | Q42284991 |
| | Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection | Q42496178 |
| | Flutamide and hepatitis | Q42697024 |
| | Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics | Q42792678 |
| | Correlation of placental microsomal activities with protein detected by antibodies to rabbit cytochrome P-450 isozyme 6 in preparations from humans exposed to polychlorinated biphenyls, quaterphenyls, and dibenzofurans. | Q44388318 |
| | A novel CYP1A1 gene polymorphism in African-Americans. | Q44606082 |
| | Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation | Q44674440 |
| | Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients | Q44734062 |
| | Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to alcoholic liver cirrhosis | Q44761197 |
| | Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. | Q46472830 |
| | Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples | Q46870575 |
| | P450 genes: evolution, regulation, and relationship to human cancer and pharmacogenetics | Q47418862 |
| | Renal Effects and Metabolism of Isoflurane in Man | Q47868711 |
| | Clinical enflurane metabolism by cytochrome P450 2E1. | Q51636774 |
| | Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. | Q51654852 |
| | Is enflurane hepatotoxic? | Q51815467 |
| | Inorganic fluoride nephrotoxicity: prolonged enflurane and halothane anesthesia in volunteers | Q52709870 |
| | Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions | Q34721135 |
| | Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors | Q35372195 |
| | Drug hypersensitivity reactions and human immunodeficiency virus disease | Q35553836 |
| | Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk | Q35594031 |
| | Metabolic activation of carcinogens | Q35853797 |
| | Human cytochromes P450: problems and prospects | Q35856204 |
| | Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? | Q35956848 |
| | Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptual tissues: implications for embryotoxicity and teratogenesis | Q36071592 |
| | The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions | Q36312078 |
| | Adverse reactions to co-trimoxazole in HIV infection | Q36509421 |
| | Molecular genetics of the debrisoquin-sparteine polymorphism | Q36522041 |
| | Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. | Q36787503 |
| | The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence | Q37355687 |
| | The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature | Q37632095 |
| | Prostaglandin H synthase and xenobiotic oxidation | Q37813447 |
| | UDP-glucuronosyltransferases: a family of detoxifying enzymes | Q37823068 |
| | Molecular mechanisms of the hepatotoxicity caused by acetaminophen | Q38027602 |
| | Drug-induced allergic hepatitis | Q38027620 |
| | Drug disposition and drug hypersensitivity | Q38172449 |
| | UDP-glucuronosyltransferases in the metabolic disposition of xenobiotics | Q38236905 |
| | The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci | Q38618586 |
| | Neoantigens associated with halothane hepatitis | Q38709418 |
| | Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes | Q38753189 |
| | The molecular biology of cytochrome P450s. | Q39572384 |
| | Formation of toxic metabolites from drugs and other xenobiotics by glutathione conjugation | Q39576357 |
| | The immunologic and metabolic basis of drug hypersensitivities | Q39647228 |
| | Basic concepts in drug metabolism: Part I. | Q39679807 |
| | Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure | Q39727500 |
| | Clinical pharmacokinetics of dapsone | Q39743290 |
| | Renal toxicity of anaesthetics: with specific reference to the nephrotoxicity of methoxyflurane | Q39924599 |
| | The hepatic effects of sevoflurane | Q40374160 |
| | Clinical Pharmacokinetics of Tacrine | Q40472033 |
| | Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications | Q40632150 |
| | Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans | Q40700883 |
| | In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. | Q40711577 |
| | Treatment of infections in the patient with acquired immunodeficiency syndrome | Q40750761 |
| | Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury | Q40817414 |
| | Metabolic polymorphisms | Q40840745 |
| | Cytochromes P450: their active-site structure and mechanism of oxidation | Q40861918 |
| | Mechanisms of halothane toxicity: novel insights | Q40866735 |
| | Renal tubular site of action of fluoride in Fischer 344 rats | Q41051768 |
| | CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses | Q53721761 |
| | The Role of Active Metabolites in Drug Toxicity | Q56474940 |
| | Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency | Q57302820 |
| | Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians | Q57302826 |
| | The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man | Q57302827 |
| | Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity | Q57302832 |
| | Bioactivation and bioinactivation of drugs and drug metabolites: Relevance to adverse drug reactions | Q57302836 |
| | An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro | Q57302847 |
| | The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: Chemical mechanisms and the effects of fluorine substitution | Q62232414 |
| | Immune responses to acetaldehyde-protein adducts: role in alcoholic liver disease | Q67593983 |
| | Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity | Q67925046 |
| | Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens | Q68129405 |
| | Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4 | Q68129421 |
| | Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis | Q68262151 |
| | Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2 | Q69624974 |
| | Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites | Q69941103 |
| | Flutamide-related fulminant hepatic failure | Q70222558 |
| | The 1- and 2-electron oxidation of acetaminophen catalyzed by prostaglandin H synthase | Q70322296 |
| | Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells | Q70386022 |
| | Mechanism of methemoglobin formation by diphenylsulfones. Effect of 4-amino-4'-hydroxyaminodiphenylsulfone and other p-substituted derivatives | Q70405638 |
| | Measurement of in vivo microsomal epoxide hydrolase activity in white subjects | Q70612062 |
| | Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe | Q70910510 |
| | Intra- and extra-cellular formation of metabolites from chemically reactive species | Q71297462 |
| | Protein-reactive metabolites of carbamazepine in mouse liver microsomes | Q71302767 |
| | Metabolism of paracetamol to a glutathione conjugate catalyzed by prostaglandin synthetase | Q71523140 |
| | Prostaglandin endoperoxide synthetase-dependent cooxidation of acetaminophen to intermediates which covalently bind in vitro to rabbit renal medullary microsomes | Q71575162 |
| | Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo* | Q71809403 |
| | Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac | Q71846432 |
| | Species variation in the bioactivation of tacrine by hepatic microsomes | Q71856356 |
| | N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes | Q71940133 |
| | Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation | Q72014034 |
| | Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? | Q72250696 |
| | Polymorphism at the P450IIE1 locus is not associated with alcoholic liver disease in Caucasian men | Q72289544 |
| | Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis | Q72371137 |
| | Acetaminophen: enzymatic formation of a transient phenoxyl free radical | Q72392475 |
| | Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human | Q72496970 |
| | Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro | Q72521285 |
| | Early stage autoinduction of carbamazepine metabolism in humans | Q72589317 |
| | Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene | Q72701476 |
| | Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease | Q72718206 |
| | Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population | Q72800543 |
| | Ethanol-derived immunoreactive species formed by free radical mechanisms | Q72827351 |
| | An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes | Q72870562 |
| | The effect of acidosis on sympatho-adrenal stimulation. Particular reference to cardiopulmonary bypass | Q72886159 |
| | Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis | Q72907446 |
| | Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils | Q72963229 |
| | Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies | Q72965320 |
| P433 | issue | 3 | |
| P304 | page(s) | 215-230 | |
| P577 | publication date | 1996-09-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism | |
| P478 | volume | 31 | |